This award furthers the capability of tissue engineering scientists to utilize the microgravity environment in their thick-tissue vascularization research.
The CASIS Innovations in Space Award adds to the New Organ Alliance portfolio by providing added benefit to winning teams from the Vascular Tissue Challenge supported by NASA. One team will be provided the opportunity to launch an experiment to the ISS National Laboratory that furthers their research on thick-tissue vascularization.
Results from research conducted in microgravity have the potential to advance the field of regenerative medicine and bring us closer to the goal of bioengineering full organs and advanced tissue constructs that may help to end the organ shortage. This award is a first step in supporting this exciting area of engineering innovation.
This prize will be awarded to a top team in the Vascular Tissue Challenge. CASIS will provide the team with up to $200,000 in flight hardware costs, along with transportation to the ISS-NL, support on station, and return of experimental samples to earth.
A review panel of scientists and subject matter experts will select recipients of the CASIS Innovations in Space Award based upon their spaceflight experiments proposed as part of the Vascular Tissue Challenge.
In 2011, NASA chose the Center for the Advancement of Science in Space (CASIS) to be the sole manager of the
International Space Station U.S. National Laboratory. The mission of CASIS is to maximize use of this unparalleled
platform for innovation, which can benefit all humankind and inspire a new generation to look to the stars.
The organization has been awarded by NASA the responsibility of inciting the imagination of entrepreneurs
and scientists alike, accelerating and facilitating space-based research as well as creating public awareness
of National Lab research and making space science more accessible to the world.
By carefully selecting research and funding projects, by connecting investors looking for opportunity to
scientists with great ideas, and by making access to the station faster and easier, CASIS will drive scientific
inquiry toward developing groundbreaking new technologies and products that will tangibly affect our lives.
New Organ's goal is to ensure no one dies from lack of a healthy organ. The New Organ Liver Prize is our first step toward that goal.
Around the world, millions of people need replacement organs, and many die before finding a suitable donor. In the United States, the wait list has skyrocketed while the number of available organs has stayed relatively flat. Even those fortunate enough to find an organ in time face serious medical difficulties, often for the rest of their lives.
The growing field of regenerative medicine offers many potential solutions, but it is drastically underfunded compared to more established areas of medicine. We're developing a challenge prize series to spur innovation in whole organ regeneration, engineering, and preservation and to help draw popular attention to this vital cause.
In order to put regenerative medicine and tissue engineering on the map as game-changing solutions to organ disease and the global organ shortage, we wanted to create a powerful focal point, and prizes are perfect for this.
Well-executed challenge prizes have launched entire industries in the past, such as the Orteig Prize won by Charles Lindbergh in 1927, which transformed U.S. aviation. Among other things, good prizes can attract new capital to seemingly intractable problems, motivate top minds and non-traditional players, galvanize public demand, force regulatory reform, encourage smart risk taking, and help transcend perceived constraints.
Right now, the New Organ Liver Prize is worth $1 million. We are actively seeking partners to increase that amount.
Many, many people have been affected by organ disease and the organ shortage crisis, if not directly, then indirectly through the suffering of friends or family members. What's more, we believe that breakthroughs in whole organ tissue engineering will act as a catalyst for accelerating regenerative technologies as a whole, and regenerative medicine is going to make all of our lives dramatically better. This belief was a key motivator for us in designing the New Organ Liver Prize.
Our initial prize, the New Organ Liver Prize, is the first in a series of challenges and awards to incentivize tissue engineering solutions for all of the complex solid organs, including the heart, kidney, lungs, and pancreas. We're also currently exploring a prize focused on organ preservation with the Organ Preservation Alliance, a coalition incubated by Singularity University Labs.
Absolutely. The New Organ Liver Prize is open to qualified teams wishing to participate from anywhere in the world.
The Methuselah Foundation (New Organ's host charity) does not claim any rights on IP produced by the prize teams.
If you haven't already, sign up as an organ donor. New Organ exists to usher in broader, longer-term solutions to the organ crisis, but donor organ transplants still save tens of thousands of lives every year right now. Take a few minutes to register at donatelife.net.
You can support New Organ directly by donating here, as well as sharing via social media.
No. The full $1 million prize will be awarded to the first registered team that can create a regenerative or bio-engineered solution that enables a large animal to survive 90 days without native liver function.
To register, please submit an Intent to Participate form to the New Organ team at least seven months before beginning trials. Register your team here: https://www.neworgan.org/prizes/liver-prize/register
Once accepted, teams will later be required to submit a Team Agreement, an Executive Summary, and a series of Team Trial Application documents to the judging committee.
The New Organ Liver Prize will be judged by a panel of five to seven independent, highly-qualified experts. We're in the process of forming the judging committee, which will be solely responsible for evaluating compliance with all prize guidelines and rules, and will have final authority in awarding the prize.